(NaturalNews) A Philadelphia jury has found drug giant Pfizer Inc. guilty of deliberately ignoring evidence that hormone replacement therapy (HRT) drug Prempro increased women's risk of breast cancer, ordering it to pay unspecified damages to defendant Connie Barton.
Millions of women used Prempro and other HRT drugs up until 2002, when the groundbreaking Women's Health Initiative study found that taking the drugs significantly increased women's risk of breast cancer and death from cardiovascular disease. The
risk was so striking that researchers called an early halt to the study out of concern for participants' lives. The
drugs were -- and still are -- marketed to relieve the symptoms of menopause, such as hot flashes, mood swings and night sweats.
More recent research suggests that
HRT drugs also increase women's risk of dying from lung cancer.
Although
Prempro was marketed by Wyeth,
Pfizer assumed liability for Wyeth's prior actions when it purchased the company in October.
According to Barton's lawyers,
Wyeth was aware of the risks of Prempro well before the release of the Women's Health Initiative
results, but made no efforts to withdraw the
drug from the market or warn women or
doctors of its effects.
"They knew back in the 1970s that these drugs had the potential to cause
breast cancer," said attorney Esther Berezofsky, "so they didn't have the studies done." When negative results began to emerge, Berezofsky said, Wyeth attempted to downplay them.
The jury agreed, ruling not only that Prempro had caused Barton's case of invasive breast
cancer, but that the drug company was to blame.
Before its acquisition, Wyeth also admitted to practices such as ghostwriting articles for publication in medical journals, promoting off-label (unapproved) uses of drugs and making lavish gifts to doctors. Pfizer claims the company has since abandoned these policies.
The Barton case is only one of 9,000 Prempro-related lawsuits filed in the United States to date. Of eight cases to go to trial, five have ended in "
guilty" verdicts for the company. Pfizer has appealed all five.
Sources for this story include:
www.dailyfinance.com.
Have comments on this article? Post them here:
people have commented on this article.
Email this article to a friend
Share this article on: 
Now Available from 
